Long-term immunogenicity of BNT162b2 vaccination in the elderly and in younger health care workers

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527 · see citing works

Adaptive immunity to SARS-CoV-2 and COVID-19

Sette, A., & Crotty, S. (2021) · Cell · doi:10.1016/j.cell.2021.01.007 · Cited by 1,860 · see citing works

Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine

Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · doi:10.1101/2021.07.28.21261159 · Cited by 1,640 · see citing works

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110345 · Cited by 1,640 · see citing works

Waning Immunity after the BNT162b2 Vaccine in Israel

Goldberg, Y., Mandel, M., Bar-On, Y. M., Bodenheimer, O., Freedman, L., Haas, E. J., Milo, R., Alroy-Preis, S., Ash, N., & Huppert, A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114228 · Cited by 1,034 · see citing works

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1

Shrotri, M., Navaratnam, A. M. D., Nguyen, V., Byrne, T., Geismar, C., Fragaszy, E., Beale, S., Fong, W. L. E., Patel, P., Kovar, J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01642-1 · Cited by 393 · see citing works

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study

Hillus, D., Schwarz, T., Tober‐Lau, P., Vanshylla, K., Hastor, H., Thibeault, C., Jentzsch, S., Helbig, E. T., Lippert, L. J., Tscheak, P., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00357-x · Cited by 343 · see citing works

Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine

Mizrahi, B., Lotan, R., Kalkstein, N., Peretz, A., Perez, G., Ben-Tov, A., Chodick, G., Gazit, S., & Patalon, T. (2021) · Nature Communications · doi:10.1038/s41467-021-26672-3 · Cited by 261 · see citing works

Correlation of SARS-CoV-2 Breakthrough Infections to Time-from-vaccine; Preliminary Study

(2021) · doi:10.1101/2021.07.29.21261317 · Cited by 261 · see citing works

Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans

Vanshylla, K., Di Cristanziano, V., Kleipass, F., Dewald, F., Schommers, P., Gieselmann, L., Gruell, H., Schlotz, M., Ercanoglu, M. S., Stumpf, R., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.04.015 · Cited by 153 · see citing works

Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany

Schwarz, T., Tober‐Lau, P., Hillus, D., Helbig, E. T., Lippert, L. J., Thibeault, C., Koch, W., Landgraf, I., Michel, J., Bergfeld, L., et al. (2021) · Emerging infectious diseases · doi:10.3201/eid2708.211145 · Cited by 75 · see citing works

Advances in COVID-19 mRNA vaccine development

Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601 · see citing works

mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant

Gruell, H., Vanshylla, K., Tober-Lau, P., Hillus, D., Schommers, P., Lehmann, C., Kurth, F., Sander, L. E., & Klein, F. (2022) · Nature Medicine · doi:10.1038/s41591-021-01676-0 · Cited by 410 · see citing works

Antibody-mediated neutralization of SARS-CoV-2

Gruell, H., Vanshylla, K., Weber, T., Barnes, C. O., Kreer, C., & Klein, F. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.005 · Cited by 145 · see citing works

Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers

Bayart, J., Douxfils, J., Gillot, C., David, C., Mullier, F., Elsen, M., Eucher, C., Eeckhoudt, S. V., Roy, T., Gérin, V., et al. (2021) · Vaccines · doi:10.3390/vaccines9101092 · Cited by 136 · see citing works

Serological Response to Three, Four and Five Doses of SARS-CoV-2 Vaccine in Kidney Transplant Recipients

Osmanodja, B., Ronicke, S., Budde, K., Jens, A., Hammett, C., Koch, N., Seelow, E., Waiser, J., Zukunft, B., Bachmann, F., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11092565 · Cited by 88 · see citing works

The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2

Townsend, J. P., Hassler, H. B., Sah, P., Galvani, A. P., & Dornburg, A. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2204336119 · Cited by 86 · see citing works

Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses

Gounant, V., Ferré, V. M., Soussi, G., Charpentier, C., Flament, H., Houhou‐Fidouh, N., Collin, G., Namour, C., Assoun, S., Bizot, A., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.10.015 · Cited by 61 · see citing works

Longitudinal dynamics of SARS-CoV-2-specific cellular and humoral immunity after natural infection or BNT162b2 vaccination

Almendro-Vázquez, P., Laguna‐Goya, R., Ruiz‐Ruigómez, M., Utrero‐Rico, A., Lalueza, A., de la Calle, G. M., Delgado, P., Ordoño, L. P., Muro, E., Vila, J. J., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1010211 · Cited by 59 · see citing works

SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients – A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease

Wagner, A., Garner‐Spitzer, E., Schötta, A., Orola, M. J., Wessely, A., Zwazl, I., Ohradanova‐Repic, A., Weseslindtner, L., Tajti, G., Gebetsberger, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.889138 · Cited by 58 · see citing works

Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article

Barrière, J., Carlès, M., Audigier-Valette, C., Ré, D., Adjtoutah, Z., Seitz‐Polski, B., Gounant, V., Descamps, D., & Zalcman, G. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.12.011 · Cited by 56 · see citing works

Duration of immunity following full vaccination against SARS-CoV-2: a systematic review

Addo, I. Y., Dadzie, F. A., Okeke, S. R., Boadi, C., & Boadu, E. F. (2022) · Archives of Public Health · doi:10.1186/s13690-022-00935-x · Cited by 53 · see citing works

BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19

Behrens, G. M. N., Barros‐Martins, J., Cossmann, A., Ramos, G. M., Stankov, M. V., Odak, I., Dopfer‐Jablonka, A., Hetzel, L., Köhler, M. I., Patzer, G. E., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32527-2 · Cited by 40 · see citing works

Durability of omicron-neutralising serum activity after mRNA booster immunisation in older adults

Vanshylla, K., Tober‐Lau, P., Gruell, H., Münn, F., Eggeling, R., Pfeifer, N., Le, N. H., Landgraf, I., Kurth, F., Sander, L. E., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00135-9 · Cited by 35 · see citing works

A multiplex protein panel assay for severity prediction and outcome prognosis in patients with COVID-19: An observational multi-cohort study

Wang, Z., Cryar, A., Lemke, O., Tober-Lau, P., Ludwig, D., Helbig, E., Hippenstiel, S., Sander, L., Blake, D., Lane, C., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101495 · Cited by 28 · see citing works

Frailty impacts immune responses to Moderna COVID-19 mRNA vaccine in older adults

Semelka, C., DeWitt, M., Blevins, M. W., Holbrook, B. C., Sanders, J. W., & Alexander‐Miller, M. A. (2023) · Immunity & Ageing · doi:10.1186/s12979-023-00327-x · Cited by 33 · see citing works

Persistence of Immune Response in Health Care Workers After Two Doses BNT162b2 in a Longitudinal Observational Study

Herzberg, J., Fischer, B., Lindenkamp, C., Becher, H., Becker, A., Honarpisheh, H., Guraya, S. Y., Strate, T. G., & Knabbe, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.839922 · Cited by 31 · see citing works

Role of antiviral CD8+ T cell immunity to SARS-CoV-2 infection and vaccination

Karl, V., Hofmann, M., & Thimme, R. (2025) · Journal of Virology · doi:10.1128/jvi.01350-24 · Cited by 34 · see citing works

Booster shot of inactivated SARS‐CoV‐2 vaccine induces potent immune responses in people living with HIV

Zhan, H., Gao, H., Liu, Y., Zhang, X., Li, H., Li, X., Wang, L., Li, C., Li, B., Wang, Y., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28428 · Cited by 27 · see citing works

Vaccine-induced correlate of protection against fatal COVID-19 in older and frail adults during waves of neutralization-resistant variants of concern: an observational study

Vikström, L., Fjällström, P., Gwon, Y.-D., Sheward, D. J., Byström, J. W., Evander, M., Bladh, O., Widerström, M., Molnár, C., Rasmussen, G., et al. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100646 · Cited by 27 · see citing works

Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study

Bruel, T., Pinaud, L., Tondeur, L., Planas, D., Staropoli, I., Porrot, F., Guivel‐Benhassine, F., Attia, M., Pelleau, S., Woudenberg, T., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101576 · Cited by 24 · see citing works

Severe Acute Respiratory Syndrome Coronavirus 2 Adaptive Immunity in Nursing Home Residents Following a Third Dose of the Comirnaty Coronavirus Disease 2019 Vaccine

Giménez, E., Albert, E., Zulaica, J., Torres, I., Rusu, L., Rodríguez-Moreno, A., Burgos, J. S., Peiró, S., Salas, D., Vanaclocha, H., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac223 · Cited by 22 · see citing works

Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review

Kreuzberger, N., Hirsch, C., Andreas, M., Böhm, L., Bröckelmann, P. J., Cristanziano, V. D., Golinski, M., Hausinger, R. I., Mellinghoff, S. C., Lange, B., et al. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015021 · Cited by 22 · see citing works

Immune defects associated with lower SARS-CoV-2 BNT162b2 mRNA vaccine response in aged people

Vitallé, J., Pérez‐Gómez, A., Ostos, F. J., Gasca‐Capote, C., Jiménez‐León, M. R., Bachiller, S., Rivas‐Jeremías, I., Silva-Sánchez, M. D. M., Ruiz-Mateos, A. M., Martín-Sánchez, M. Á., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.161045 · Cited by 21 · see citing works

Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals

Terpos, E., Karalis, V., Ntanasis-Stathopoulos, I., Apostolakou, F., Gumeni, S., Gavriatopoulou, M., Papadopoulos, D., Malandrakis, P., Papanagnou, E.-D., Korompoki, E., et al. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000677 · Cited by 20 · see citing works

Neutralizing Response Against SARS-CoV-2 Variants 8 Months After BNT162b2 Vaccination in Naive and COVID-19–Convalescent Individuals

Luczkowiak, J., Labiod, N., Rivas, G. A., Rolo, M., Lasala, F., Lora‐Tamayo, J., Mancheño‐Losa, M., Rial‐Crestelo, D., Pérez‐Rivilla, A., Folgueira, M. D., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab634 · Cited by 19 · see citing works

The ageing immune system as a potential target of senolytics

Du, P. Y., Gandhi, A., Bawa, M., & Gromala, J. (2023) · Oxford Open Immunology · doi:10.1093/oxfimm/iqad004 · Cited by 18 · see citing works

Factors Influencing Level and Persistence of Anti SARS-CoV-2 IgG after BNT162b2 Vaccine: Evidence from a Large Cohort of Healthcare Workers

Costa, C. S., Migliore, E., Galassi, C., Scozzari, G., Ciccone, G., Coggiola, M., Pira, E., Scarmozzino, A., Valle, G. L., Cassoni, P., et al. (2022) · Vaccines · doi:10.3390/vaccines10030474 · Cited by 18 · see citing works

Decoding T cell senescence in cancer: Is revisiting required?

Magkouta, S., Markaki, E., Evangelou, K., Petty, R., Verginis, P., & Gorgoulis, V. G. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.11.003 · Cited by 17 · see citing works

Skewed fate and hematopoiesis of CD34+ HSPCs in umbilical cord blood amid the COVID-19 pandemic

Estep, B. K., Kuhlmann, C. J., Osuka, S., Suryawanshi, G. W., Nagaoka-Kamata, Y., Samuel, C. N., Blucas, M. T., Jepson, C. E., Goepfert, P., & Kamata, M. (2022) · iScience · doi:10.1016/j.isci.2022.105544 · Cited by 15 · see citing works

Dynamics of humoral and T-cell immunity after three BNT162b2 vaccinations in adults older than 80 years

Romero-Olmedo, A. J., Schulz, A. R., Hochstätter, S., Gupta, D. D., Hirseland, H., Staudenraus, D., Camara, B., Volland, K., Hefter, V., Sapre, S., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00219-5 · Cited by 15 · see citing works

Low But Recoverable Markers of Humoral Immune Response to BNT162b2 in Elderly LTCF Residents Five to Seven Months After Two-Dose Vaccination

Delbrück, M., Hoehl, S., Toptan, T., Schenk, B., Grikscheit, K., Metzler, M., Herrmann, E. M., & Ciesek, S. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.883724 · Cited by 13 · see citing works

Booster or additional vaccination doses in patients vaccinated against COVID-19

Botella, A. G., García‐Lledó, A., Gómez‐Pavón, J., del Castillo, J. M. G., Hernández‐Sampelayo, T., Delgado, M. C. M., Martín‐Sánchez, F. J., Martínez‐Sellés, M., Molero, J., Guillén, S. M., et al. (2021) · Revista Española de Quimioterapia · doi:10.37201/req/149.2021 · Cited by 11 · see citing works

Neutralizing antibody responses 300 days after SARS‐CoV‐2 infection and induction of high antibody titers after vaccination

Urlaub, D., Wolfsdorff, N., Hoffmann, J., Dorok, S., Hoffmann, M., Anft, M., Pieris, N., Günther, P. S., Schaaf, B., Cassens, U., et al. (2022) · European Journal of Immunology · doi:10.1002/eji.202149758 · Cited by 11 · see citing works

Durable immune responses after BNT162b2 vaccination in home-dwelling old adults

Hansen, L., Brokstad, K. A., Bansal, A., Zhou, F., Bredholt, G., Onyango, T. B., Sandnes, H. H., Elyanow, R., Madsen, A., Trieu, M.-C., et al. (2023) · Vaccine X · doi:10.1016/j.jvacx.2023.100262 · Cited by 12 · see citing works

Vaccines and Vaccination against SARS-CoV-2: Considerations for the Older Population

Weinberger, B. (2021) · Vaccines · doi:10.3390/vaccines9121435 · Cited by 10 · see citing works

Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis

Papadopoulos, D., Ntanasis‐Stathopoulos, I., Gavriatopoulou, M., Evangelakou, Z., Malandrakis, P., Manola, M. S., Gianniou, D. D., Kastritis, E., Trougakos, I. P., Dimopoulos, M. A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10020204 · Cited by 10 · see citing works

Decline of Humoral Responses 6 Months after Vaccination with BNT162b2 (Pfizer–BioNTech) in Patients on Hemodialysis

Jahn, M., Korth, J., Dorsch, O., Anastasiou, O. E., Krawczyk, A., Brochhagen, L., van de Sand, L., Sorge-Hädicke, B., Tyczynski, B., Witzke, O., et al. (2022) · Vaccines · doi:10.3390/vaccines10020327 · Cited by 9 · see citing works

Kinetics of COVID-19 mRNA primary and booster vaccine-associated neutralizing activity against SARS-CoV-2 variants of concern in long-term care facility residents: a prospective longitudinal study in Japan

Kakugawa, T., Doi, K., Ohteru, Y., Kakugawa, H., Oishi, K., Kakugawa, M., Hirano, T., Mimura, Y., & Matsunaga, K. (2023) · Immunity & Ageing · doi:10.1186/s12979-023-00368-2 · Cited by 7 · see citing works

Immunogenicity of COVID-19 Vaccinations in Hematological Patients: 6-Month Follow-Up and Evaluation of a 3rd Vaccination

Schubert, L., Koblischke, M., Schneider, L., Porpaczy, E. A., Winkler, F., Jaeger, U., Blüml, S., Haslacher, H., Burgmann, H., Aberle, J. H., et al. (2022) · Cancers · doi:10.3390/cancers14081962 · Cited by 9 · see citing works

Third BNT162b2 Vaccine Booster Dose against SARS-CoV-2-Induced Antibody Response among Healthcare Workers

Hussein, K., Dabaja‐Younis, H., Szwarcwort‐Cohen, M., Almog, R., Leiba, R., Weissman, A., Mekel, M., Hyams, G., Horowitz, N. A., Gepstein, V., et al. (2022) · Vaccines · doi:10.3390/vaccines10101741 · Cited by 8 · see citing works

Antibody response dynamics to CoronaVac vaccine and booster immunization in adults and the elderly: A long-term, longitudinal prospective study

Volpe, G. J., Vessoni, S. C. S., Soares, L. B., Almeida, M. A. A. L. D. S., Braga, P. E., de Moraes, G. R., Ferreira, N. N., Garibaldi, P. M. M., Kashima, S. H., da Fonseca, B. A. L., et al. (2023) · IJID Regions · doi:10.1016/j.ijregi.2023.04.003 · Cited by 8 · see citing works

Inactivated SARS-CoV-2 booster vaccine enhanced immune responses in patients with chronic liver diseases

Liu, Y., Lu, J., Zhan, H., Yuan, W., Li, X., Kang, H., Li, H., Chen, Y., Cheng, L., Sun, X., et al. (2023) · Virologica Sinica · doi:10.1016/j.virs.2023.07.005 · Cited by 7 · see citing works

Kinetics of pro- and anti-inflammatory spike-specific cellular immune responses in long-term care facility residents after COVID-19 mRNA primary and booster vaccination: a prospective longitudinal study in Japan

Kakugawa, T., Mimura, Y., Mimura‐Kimura, Y., Doi, K., Ohteru, Y., Kakugawa, H., Oishi, K., Kakugawa, M., Hirano, T., & Matsunaga, K. (2024) · Immunity & Ageing · doi:10.1186/s12979-024-00444-1 · Cited by 6 · see citing works

Functional antibody responses targeting the Spike protein of SARS-CoV-2 Omicron XBB.1.5 in elderly nursing home residents following Wuhan-Hu-1-based mRNA booster vaccination

Sánchez‐Simarro, Á., Fernández‐Soto, D., Grau, B., Albert, E., Giménez, E., Avilés‐Alía, A. I., Gozalbo‐Rovira, R., Rusu, L., Olea, B., Geller, R., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-62874-7 · Cited by 5 · see citing works

Higher plasma levels of thymosin-α1 are associated with a lower waning of humoral response after COVID-19 vaccination: an eight months follow-up study in a nursing home

Pozo‐Balado, M. D. M., Bulnes‐Ramos, Á., Olivas‐Martínez, I., Garrido‐Rodríguez, V., Lozano, C., Álvarez‐Ríos, A. I., Sánchez-Sánchez, B., Sánchez-Bejarano, E., Maldonado-Calzado, I., Martín-Lara, J. M., et al. (2023) · Immunity & Ageing · doi:10.1186/s12979-023-00334-y · Cited by 5 · see citing works

Interoperable, Domain-Specific Extensions for the German Corona Consensus (GECCO) COVID-19 Research Data Set Using an Interdisciplinary, Consensus-Based Workflow: Data Set Development Study

Lichtner, G., Haese, T., Brose, S., Röhrig, L., Lysyakova, L., Rudolph, S., Uebe, M., Saß, J., Bartschke, A., Hillus, D., et al. (2023) · JMIR Medical Informatics · doi:10.2196/45496 · Cited by 6 · see citing works

Antibody response to inactivated COVID ‐19 vaccine in patients with type 2 diabetes mellitus after the booster immunization

Li, H., Wang, Y., Li, X., Wang, S., Feng, X., Xiao, X., & Li, Y. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13448 · Cited by 4 · see citing works

Neutralization sensitivity of the SARS-CoV-2 Omicron BA.2.75 sublineagePreprint

Gruell, H., Vanshylla, K., Tober‐Lau, P., Hillus, D., Sander, L. E., Kurth, F., & Klein, F. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.04.502609 · Cited by 4 · see citing works

Temporal dynamics of SARS-CoV-2 antibodies and IgG subclasses following multiple doses and diverse COVID-19 vaccine combinations

Meyer, J., Hoerauf, A. M., Dubiel, A. E., Kovačević, P., Trudić, A., Primorac, D., Hübner, M. P., Adjobimey, T., & Parčina, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1727049 · Cited by 3 · see citing works

Factors Associated with Impaired Humoral Immune Response to mRNA Vaccines in Patients with Inflammatory Bowel Disease: A Matched-Cohort Analysis from the RisCoin Study

Csollarova, K., Koletzko, L., Thi, T. G. L., Wratil, P. R., Zhelyazkova, A., Breiteneicher, S., Stern, M., Lupoli, G., Schwerd, T., Choukèr, A., et al. (2025) · Vaccines · doi:10.3390/vaccines13070673 · Cited by 2 · see citing works

ERS International Congress 2021: highlights from the Respiratory Infections Assembly

Meldrum, O. W., Belchamber, K. B. R., Chichirelo-Konstantynovych, K. D., Horton, K. L., Konstantynovych, T. V., Long, M. B., McDonnell, M. J., Perea, L., García‐Basteiro, A. L., Loebinger, M. R., et al. (2022) · ERJ Open Research · doi:10.1183/23120541.00642-2021 · Cited by 2 · see citing works

Development of interoperable, domain-specific extensions for the German Corona Consensus (GECCO) COVID-19 research dataset using an interdisciplinary, consensus-based workflowPreprint

Lichtner, G., Haese, T., Brose, S., Röhrig, L., Lysyakova, L., Rudolph, S., Uebe, M., Saß, J., Bartschke, A., Hillus, D., et al. (2022) · medRxiv · doi:10.1101/2022.05.12.22274089 · Cited by 2 · see citing works

Six‐month BNT162b2 vaccine efficacy in adolescents and young adults with cancer

Donzé, C., Ninove, L., de Lamballerie, X. N., Saultier, P., & André, N. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29547 · Cited by 1 · see citing works

Особливості вегетативних розладів у хворих на COVID-19

Vodopianov, V. A., Strelchenko, O. S., Malyshev, V. V., Krivonos, M. Y., Kosse, M. Y., & Demydenko, D. P. (2022) · INTERNATIONAL NEUROLOGICAL JOURNAL · doi:10.22141/2224-0713.17.8.2021.250820 · Cited by 1 · see citing works

Immunogenicity assessment of elder hepatocellular carcinoma patients after inactivated whole-virion SARS-CoV-2 vaccination

Gao, R., Zheng, C., Yang, M., Dai, L., Chen, C., Yao, J., Zhang, Z., Tang, L. M., Shi, Y., & Han, X. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2274484 · Cited by 1 · see citing works

Anti‐spike protein IgG antibody responses up to 3 months after the third dose of the BNT162b2 mRNA vaccine in medical care workers

Hirano, H. (2024) · Journal of General and Family Medicine · doi:10.1002/jgf2.688 · Cited by 1 · see citing works

Declining Course of Humoral Immune Response in Initially Responding Kidney Transplant Recipients after Repeated SARS-CoV-2 Vaccination

Ronicke, S., Osmanodja, B., Budde, K., Jens, A., Hammett, C., Koch, N., Zukunft, B., Bachmann, F., Choi, M., Weber, U., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11123291 · Cited by 1 · see citing works

Vaccine-induced correlate of protection against fatal COVID-19 in the old and frail during waves of neutralization resistant variants of concernPreprint

Vikström, L., Fjällström, P., Gwon, Y.-D., Sheward, D. J., Byström, J. W., Evander, M., Bladh, O., Widerström, M., Molnár, C., Rasmussen, G., et al. (2023) · medRxiv · doi:10.1101/2023.02.16.23286009 · Cited by 1 · see citing works

Impfung gegen coronavirus disease 2019 (COVID-19)

Weinberger, B. (2022) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-022-02102-x

SARS-CoV-2 Alpha-Variant Outbreak Amongst a Partially Vaccinated Long-Term Care Facility Population in The Netherlands—Phylogenetic Analysis and Infection Control Observations

der Moeren, N. V., Weterings, V. A. T. C., Pas, S. D., Verweij, J. J., van den Bijllaardt, W., Geurts, J., Zwart, V. F., Lodder, E. B., Kluytmans, J. A. J. W., Murk, J., et al. (2022) · Pathogens · doi:10.3390/pathogens11101070

Impacts of viral pathogenesis and vaccine immunization on the host humoral immune response in SARS-CoV-2 and associated variants of concern (VOCs) infection

Chowdhury, S. R., Chakrabarty, S., Chakraborti, M., & Das, A. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-85730-7.00009-6

How many is good enough? An analysis of serological follow-up after vaccination against SARS-CoV-2

Stępień, M., Zalewska, M., Kuźniarski, A., Jankowska‐Polańska, B., Piwowar, A., Świątoniowska-Lonc, N., & Knysz, B. (2023) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.2478/ahem-2023-0020

Kinetics of pro- and anti-inflammatory spike-specific T-cell responses in long-term care facility residents after COVID-19 mRNA primary and booster vaccination: A prospective longitudinal study in JapanPreprint

Kakugawa, T., Mimura, Y., Mimura‐Kimura, Y., Doi, K., Ohteru, Y., Kakugawa, H., Oishi, K., Kakugawa, M., Hirano, T., & Matsunaga, K. (2024) · Research Square · doi:10.21203/rs.3.rs-4015330/v1

Additional file 1 of Kinetics of pro- and anti-inflammatory spike-specific cellular immune responses in long-term care facility residents after COVID-19 mRNA primary and booster vaccination: a prospective longitudinal study in Japan

Kakugawa, T., Mimura, Y., Mimura‐Kimura, Y., Doi, K., Ohteru, Y., Kakugawa, H., Oishi, K., Kakugawa, M., Hirano, T., & Matsunaga, K. (2024) · Figshare · doi:10.6084/m9.figshare.26085092

Additional file 2 of Kinetics of pro- and anti-inflammatory spike-specific cellular immune responses in long-term care facility residents after COVID-19 mRNA primary and booster vaccination: a prospective longitudinal study in Japan

Kakugawa, T., Mimura, Y., Mimura‐Kimura, Y., Doi, K., Ohteru, Y., Kakugawa, H., Oishi, K., Kakugawa, M., Hirano, T., & Matsunaga, K. (2024) · Figshare · doi:10.6084/m9.figshare.26085193

Additional file 1 of Frailty impacts immune responses to Moderna COVID-19 mRNA vaccine in older adults

Semelka, C., DeWitt, M. E., Blevins, M. W., Holbrook, B. C., Sanders, J. W., & Alexander‐Miller, M. A. (2024) · Figshare · doi:10.6084/m9.figshare.26561866

The immune response of the mRNA vaccine CS-2034 as a heterologous booster before and after breakthrough infection: A follow-up study

Wu, J., Meng, H., Guo, X., Liu, L., Zhou, G.-H., Liu, W.-Q., Qi, X.-Y., & Li, J.-X. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128575

Hybrid heterologous immunity shapes robust antiviral responses in children and minimizes age-related immunological differencesPreprint

Elling, R., Eisner, M., Karl, V., Seger, F., Willems, A., Bdeir, N., Eckert, D., Jacobsen, H., Maaß, H., Bauersfeld, L., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9365291/v1

Durable immune responses after BNT162b2 vaccination in home-dwelling old adults

Hansen, L., Brokstad, K. A., Bansal, A., Zhou, F., Bredholt, G., Onyango, T. B., Sandnes, H. H., Elyanow, R., Madsen, A., Trieu, M.-C., et al. (2023) · Vaccine X · doi:10.1016/j.jvacx.2023.100262 · Cited by 12 · see citing works

Low But Recoverable Markers of Humoral Immune Response to BNT162b2 in Elderly LTCF Residents Five to Seven Months After Two-Dose Vaccination

Delbrück, M., Hoehl, S., Toptan, T., Schenk, B., Grikscheit, K., Metzler, M., Herrmann, E. M., & Ciesek, S. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.883724 · Cited by 13 · see citing works

Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination

Müller, L., Andrée, M., Moskorz, W., Drexler, I., Walotka, L., Grothmann, R., Ptok, J., Hillebrandt, J., Ritchie, A., Rabl, D., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab381 · Cited by 511 · see citing works

Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2

Collier, D. A., Ferreira, I. A. T. M., Kotagiri, P., Datir, R. P., Lim, E. Y., Touizer, E., Meng, B., Abdullahi, A., The CITIID-NIHR BioResource COVID-19 Collaboration, Principal Investigators, et al. (2021) · Nature · doi:10.1038/s41586-021-03739-1 · Cited by 751 · see citing works

Immune Responses Against SARS-CoV-2 WT and Delta Variant in Elderly BNT162b2 Vaccinees

Jäger, M., Sonnleitner, S. T., Dichtl, S., Lafon, E., Diem, G., Walder, G., Lass‐Flörl, C., Wilflingseder, D., & Posch, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.868361 · Cited by 6 · see citing works